152 related articles for article (PubMed ID: 26966176)
1. Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.
Greenplate AR; Johnson DB; Roussel M; Savona MR; Sosman JA; Puzanov I; Ferrell PB; Irish JM
Cancer Immunol Res; 2016 Jun; 4(6):474-480. PubMed ID: 26966176
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
Sun JF; Yang B; Zhang L; Huang Y; Yang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
5. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibition for advanced mucosal melanoma.
Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
[TBL] [Abstract][Full Text] [Related]
7. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.
Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
9. PD-1 Blockade Expands Intratumoral Memory T Cells.
Ribas A; Shin DS; Zaretsky J; Frederiksen J; Cornish A; Avramis E; Seja E; Kivork C; Siebert J; Kaplan-Lefko P; Wang X; Chmielowski B; Glaspy JA; Tumeh PC; Chodon T; Pe'er D; Comin-Anduix B
Cancer Immunol Res; 2016 Mar; 4(3):194-203. PubMed ID: 26787823
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
15. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
16. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Mukherjee S; Ibrahimi S; Aljumaily R; Cherry M
Am J Ther; 2018; 25(6):e711-e712. PubMed ID: 29394170
[No Abstract] [Full Text] [Related]
18. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]